In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Kodiak Sciences nets $298mm via FOPO

Executive Summary

Ophthalmic-focused Kodiak Sciences Inc. netted $298mm in a follow-on offering of 6.9mm common shares (including the overallotment) at $46 each. The company will use some of the funds to move its KSI301 towards the BLA filing in retinal vein occlusion and for sBLA submissions (expected in 2022) for wet age-related macular degeneration, diabetic macular edema (DME), and possibly diabetic retinopathy without DME. Additional funds will support development of additional pipeline candidates including KSI501 for DME and uveitis. Just one day prior to the offering, Kodiak sold Baker Bros. a capped 4.5% royalty on net sales of KSI301 in exchange for $225mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register